Itamar Medical Ltd. announced that Health Care Service Corporation (HCSC) has issued a positive coverage decision that includes Home Sleep Apnea tests (HSATs) utilizing Peripheral Arterial Tonometry (PAT™) such as the company’s WatchPAT™ as medically necessary. The updated policy decision from HCSC adds approximately 14.5 million beneficiaries of five Blue Cross Blue Shield (BCSC) plans of Illinois, Texas, Oklahoma, New Mexico and Montana. The added benefit becomes effective on March 25, 2021. In November 2020 BCBS of Louisiana, covering 1.5 million lives, also published updated medical policy including PAT based HSATs. WatchPAT, based on the PAT™ technology, oximetry and actigraphy, is used for diagnosing Sleep Apnea in the home environment. Itamar Medical’s WatchPAT ONE is the only FDA-approved single-use HSAT that meets Practice Guidelines currently available on the market. This updated policy decision follows an assessment of Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome released by Blue Cross Blue Shield Association Evidence Street in July 2019.